HIPEC is a specialised cancer treatment that combines cytoreductive surgery with heated chemotherapy delivered inside the abdominal cavity. It may be considered for selected patients with cancer affecting the peritoneum — the lining inside the abdomen.

For patients travelling from the United States, United Kingdom, Middle East, Africa, South Asia and other regions, the decision to explore HIPEC is significant. It involves medical records, specialist opinions, complex surgery, recovery planning and practical travel arrangements. This guide explains the process in clear language so patients and families can make informed next-step decisions.

Doctor Visit Bangalore provides independent coordination support for patients seeking cancer treatment in Bengaluru. We help organise reports, request appointments, plan travel and accommodation, and support international patients through the practical side of their treatment journey. Medical decisions remain with the treating surgical-oncology and multidisciplinary cancer team.

The idea behind intraperitoneal chemotherapy developed from a practical problem in cancer treatment. Some cancers spread primarily within the abdominal cavity, creating deposits on the peritoneal lining and nearby organs. Systemic chemotherapy remains important, but it may not always deliver the same level of local exposure to tumour deposits on the peritoneal surface.

Surgeons and oncologists began exploring whether chemotherapy could be delivered directly into the abdominal cavity. Over time, this evolved into approaches that combined tumour-reduction surgery with chemotherapy perfusion. The addition of heat was based on laboratory and clinical observations suggesting that higher temperatures may enhance the local effect of certain anti-cancer drugs.

Modern HIPEC developed alongside cytoreductive surgery. Instead of treating the abdominal cavity without removing visible disease, specialist teams focused on removing visible tumour deposits first — making HIPEC’s role more specific: treating possible microscopic disease remaining on the peritoneal surface after surgery.

Today, HIPEC is not one fixed operation. Surgical techniques, chemotherapy drugs, perfusion duration, temperature, patient selection and evidence differ across cancer types and treatment centres.

HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. Hyperthermic means heated. Intraperitoneal means inside the abdominal cavity. HIPEC is delivered during surgery under general anaesthesia after cytoreductive surgery (CRS) removes visible cancer deposits.

After surgery, warmed chemotherapy fluid is circulated inside the abdomen through specialised tubing for a planned duration based on the cancer type and protocol. Once the perfusion is completed, the fluid is removed and the surgical procedure is finished.

The chemotherapy drug used for HIPEC depends on the primary cancer, pathology, previous treatment, kidney function, surgical protocol and the treating team’s approach. There is no single HIPEC medicine appropriate for every cancer.

Drugs used in HIPEC protocols may include mitomycin C, oxaliplatin, cisplatin, doxorubicin and other agents in selected situations.

HIPEC suitability depends on more than the diagnosis. A specialist team reviews the cancer origin, pathology, amount and location of disease, response to earlier treatment, overall health, nutrition, organ function and the expected ability to remove visible disease.

Some patients need diagnostic laparoscopy before final treatment planning. Good patient selection protects patients from undergoing a major operation that is unlikely to offer meaningful benefit.

The Peritoneal Cancer Index — PCI — is a scoring system used to describe the amount and distribution of cancer inside the abdominal cavity. It helps surgical teams assess how extensive peritoneal disease may be and whether cytoreductive surgery is likely to be feasible.

The abdomen is divided into several regions. Each region is assessed for tumour size or disease extent. These findings are combined into a PCI score. A lower or higher score does not carry the same meaning for every cancer type.

PCI is one part of the decision. It does not replace pathology, imaging, surgical judgement, treatment response, patient fitness or discussion of goals.

The role of CRS and HIPEC differs across cancer types. Evidence, patient selection criteria, chemotherapy protocols and expected outcomes vary significantly between disease settings.

Evidence for HIPEC must be interpreted by cancer type and clinical setting. A study in one cancer type, using one chemotherapy drug and one perfusion duration, cannot automatically be applied to another disease or treatment protocol.

A major randomised colorectal-cancer trial found that adding a short-course oxaliplatin HIPEC regimen to cytoreductive surgery did not improve overall survival compared with surgery alone. This shows why patients should ask about the exact regimen and evidence.

For selected patients with stage III epithelial ovarian cancer undergoing interval cytoreductive surgery after neoadjuvant chemotherapy, a major clinical trial found benefit from adding HIPEC. This result does not mean HIPEC is appropriate for every ovarian-cancer stage or setting.

CRS and HIPEC involves several sequential stages under general anaesthesia. Understanding this process helps patients and families prepare for what to expect.

Recovery after CRS and HIPEC varies greatly. The extent of surgery, organs treated, blood loss, chemotherapy exposure, nutrition, medical conditions and complications all affect how quickly a patient regains strength.

Many patients experience fatigue, pain, reduced appetite, slow return of bowel function and gradual improvement in mobility. Recovery is usually measured in weeks to months rather than days. Families should plan for a flexible timeline.

Patients travelling internationally should not book a fixed return flight before the treating team confirms that travel is medically safe.

CRS and HIPEC is major surgery. Every patient should receive a personalised discussion of risks before treatment is chosen. Potential complications can include bleeding, infection, wound problems, pneumonia, blood clots, bowel leak, bowel obstruction, kidney injury, electrolyte imbalance, stoma-related issues, need for re-operation and chemotherapy-related side effects.

After CRS and HIPEC, follow-up is important because recurrence can occur. The pattern and risk of recurrence vary by cancer type, pathology, completeness of cytoreduction, disease biology and additional systemic treatment.

Follow-up may include clinical review, symptom assessment, blood tests, tumour markers, imaging and discussion of ongoing treatment. Patients returning to another country should leave India with complete records — operative notes, discharge summary, final pathology, medication list, imaging reports, follow-up instructions and contact details for the treating team.

Recurrence does not always mean the same treatment will be repeated. Options may include systemic therapy, surgery for selected disease, repeat assessment, clinical trials or symptom management depending on the situation.

HIPEC research continues to evolve. Current work focuses on improving patient selection, understanding which chemotherapy agents are most appropriate, refining perfusion protocols, identifying molecular features that predict response and reducing complications through better surgical and recovery pathways.

Emerging areas include personalised treatment selection based on tumour biology, improved imaging of peritoneal disease, AI-assisted assessment, pressurised intraperitoneal aerosol chemotherapy in selected research settings, and repeat HIPEC evaluation.

This page is for general education and medical-tourism coordination only. It does not provide medical advice, diagnosis, treatment recommendations or guaranteed outcomes. HIPEC suitability, expected benefit, surgical risk, treatment cost, hospital stay, recovery time and travel fitness must be assessed directly by the treating surgical-oncology and multidisciplinary cancer team.

Last reviewed: July 2026. Recommended editorial review cycle: every 12 months, or earlier if key HIPEC guidelines, trials or treatment standards change.

• National Cancer Institute — HIPEC definition
• PRODIGE 7 randomised trial — CRS with or without oxaliplatin HIPEC for colorectal peritoneal metastases
• Hyperthermic intraperitoneal chemotherapy in ovarian cancer clinical trial
• Canadian guidelines on management of colorectal peritoneal metastases